|Trade names||Maxalt, others|
|Metabolism||by monoamine oxidase|
|Elimination half-life||2–3 hours|
|Excretion||82% urine; 12% faeces|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||269.345 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches. It should be used as soon as the headache starts. It is taken by mouth.
Common side effects include chest pain, dizziness, dry mouth, and tingling. Other side effects may include myocardial infarction, stroke, high blood pressure, serotonin syndrome, and anaphylaxis. Excessive use may result in medication overuse headaches. Use is not recommended during pregnancy and breastfeeding is not recommended within 24 hours after taking a dose. Rizatriptan is in the triptan class and is believed to work by activating the 5-HT1 receptor.
Rizatriptan was patented in 1991 and came into medical use in 1998. It is avaliable as a generic medication. A dose in the United Kingdom costs the NHS about 3.10 £ as of 2019. In the United States the wholesale cost of this amount is about 0.73 USD. In 2016 it was the 232nd most prescribed medication in the United States with more than 2 million prescriptions.
- serotonin syndrome when used with MAOIs
- coronary artery vasospasm
- transient myocardial ischemia
- myocardial infarction
- ventricular tachycardia
- ventricular fibrillation
- hypertensive crisis
Ear, nose, and throat:
Mechanism of action
Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors. Like the other triptans sumatriptan and zolmitriptan, rizatriptan induces vasoconstriction—possibly by inhibiting the release of calcitonin gene-related peptide from sensory neurons in the trigeminal nerve.
Society and culture
Brandnames include Bizaliv, Rizalt, and Maxalt.
- "Rizatriptan Benzoate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 473. ISBN 9780857113382.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 9783527607495.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
- "Rizatriptan". MedlinePlus. U.S. National Library of Medicine.
- Millson, D; Tepper, S (2000). "Migraine pharmacotherapy with oral triptans: a rational approach to clinical management". Expert Opin Pharmacother. 1 (3): 391–404. doi:10.1517/146565126.96.36.1991. PMID 11249525.
- Wellington, K; Plosker, G. L. (2002). "Rizatriptan: An update of its use in the management of migraine". Drugs. 62 (10): 1539–74. doi:10.2165/00003495-200262100-00007. PMID 12093318.